PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations from parp Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Dr Hedy Kindler talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the POLO trial looking at the use of the PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutationsnnShe explains that this trial is the first phase III trial showing that a targeted treatment in a biomarker selective group of pancreatic cancer patients can improve progression free survival.nnDr Kindler reports that patients who received ol